Accepted at 8:27 a.m. Oct, 31, 2024 by DillingerMed
Author: marcoPOLOL
Related Note: 1474503607320
Rationale for change

Mnemonic submission: "Breathing Becomes More Problematic" (Busulfan, Bleomycin, Methotrexate, and Procarbazine). The first letters of each word matches with the first letter of each neoplastic drugs that can cause restrictive lung disease. It is catchy and relevant.

Extra Extra
Text
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Empty field
Sketchy
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Empty field
Bootcamp
OME
Additional Resources
Empty field
One by one
Empty field
#AK_Step1_v12::#Bootcamp::Pathology::02_Cellular_Injury_&_Neoplasia::10_Cell_Cycle_Dependent_Drug_Targets #AK_Step1_v12::#Physeo::11_Pathology::03_Pulmonary_Pathology::08_Restrictive_Lung_Diseases #AK_Step1_v12::#OME::Clinical::Internal_Medicine::Pulmonology::Diffuse_Parenchymal_Lung_Disease #AK_Step1_v12::#Bootcamp::Pathology::02_Cellular_Injury_&_Neoplasia::11_Cell_Cycle_Independent_Drug_Targets #AK_Other::#AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Respiratory::Respiratory_Pathology #AK_Step2_v12::#SketchyIM::09_Infectious_Diseases::02_Lung_Infections::01_Pneumonia_SOA #AK_Step2_v12::#COMBANK::53630 #AK_Step2_v12::#AMBOSS::8vaOb5 #AK_Step1_v12::#Pixorize::03_Pharmacology::12_Oncology_Pharm::01_Bleomycin #AK_Step1_v12::#Bootcamp::Pulmonology::06_Restrictive_Lung_Disease::02_Pulmonary_Fibrosis #AK_Step1_v12::#B&B::20_Pulm::02_Obstructive_and_Restrictive_Diseases::04_Restrictive_Lung_Disease::Extra #AK_Step2_v12::#Resources_by_rotation::IM::ome::pulm::dpld #AK_Step2_v12::#OME::01_Medicine::02_Pulmonology::07_DPLD #AK_Step1_v12::#SketchyPharm::08_Antineoplastics::02_DNA_&_Cellular_Division::03_Cytotoxic_Antibiotics #AK_Step2_v12::#SketchyIM::03_Pulmonology::09_Retired_Lessons::03_Restrictive_Pulmonary_Diseases::01_Interstitial_Lung_Disease_Intro_Extrinsic_ILDs_SOAP_[OLD_VERSION] #AK_Step1_v12::#SketchyPharm::08_Antineoplastics::02_DNA_&_Cellular_Division::01_Alkylating_Agents::zanki_extra #AK_Step1_v12::#Low/HighYield::2-RelativelyHighYield #AK_Step1_v12::#SketchyPharm::08_Antineoplastics::02_DNA_&_Cellular_Division::01_Alkylating_Agents #AK_Step1_v12::#Pixorize::03_Pharmacology::12_Oncology_Pharm::07_Busulfan #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::21_Key_chemotoxicities #AK_Step1_v12::#SketchyPharm::08_Antineoplastics::01_Antimetabolites::01_Methotrexate,_Leucovorin,_5-fluorouracil,_Hydroxyurea #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::04_Oncology::03_Hodgkin_Lymphoma_SOAP #AK_Step1_v12::^Systems::Respiratory::Pathology #AK_Step1_v12::#SketchyPath::03_Pulmonary::02_Restrictive_Lung_Disease::02_Idiopathic_Pulmonary_Fibrosis #AK_Step1_v12::^Other::^FA_Updates::FA2018 #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::08_Principles_of_Oncology_and_Therapeutics::11_Cell_Cycle_Independent_Drug_Targets #PANCE::HEME::neoplasms_premalignancies_malignancies #AK_Step2_v12::#SketchyIM::03_Pulmonology::07_Pulmonary_DDx::04_Chronic_Dyspnea_DDx_Part_2 #AK_Step1_v12::^Other::^EXPN::BGedit #AK_Step2_v12::#B&B::14_Pulmonary_Critical_Care::01_Pulmonary_Disease::05_Restrictive_Lung_Disease::Extra #AK_Step1_v12::#FirstAid::16_Respiratory::04_Pathology::09_Restrictive_lung_diseases::*Interstitial_Causes::Basics